More benign for BPH

Marketed treatments for benign prostatic hyperplasia (BPH) have side effects such as hypotension or sexual dysfunction. BioXell S.p.A. says that its BXL-628 vitamin D3 analog is the first compound to reduce prostatic volume in clinical trials without causing such side effects. The company believes this is because BXL-628 has a different mechanism of action than drugs marketed for BPH.

In a Phase IIa trial in 120 patients, those receiving BXL-628 had a 7.2% average reduction in prostate volume compared with placebo, the primary endpoint (p<0.0001). Results of the 12-week, double-blind, Italian trial were to be announced today...